SCHEMBL5416282

SCHEMBL5416282

COc1ccc(/C=C/S(=O)(=O)O)cc1.NC(=O)c1ccc(F)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.45
MAOB P27338 1/20 0.45
CTSL P07711 1/20 0.45
GPR183 P32249 1/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RELA Q04206 1/20 0.41
AHR P35869 1/20 0.41
NQO2 P16083 1/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5420215 0.88 NFE2L2 (0.48) NFE2L2MAOB
SCHEMBL5411555 0.87 MAOB (0.49) NFE2L2MAOBGPR183SMN1; SMN2RELA
SCHEMBL28775723 0.87 MAOB (0.49) NFE2L2MAOBGPR183SMN1; SMN2RELA
SCHEMBL5404072 0.87 CA2 (0.40) MAOBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL27738950 0.87 CA2 (0.40) MAOBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5418978 0.84 HTR2A (0.43) MAOBGPR183SMN1; SMN2
SCHEMBL27717765 0.84 HTR2A (0.43) MAOBGPR183SMN1; SMN2
SCHEMBL4258491 0.84 NPC1 (0.42) NFE2L2MAOBSMN1; SMN2TUBB4ATUBB
SCHEMBL5407438 0.83 PTGES2 (0.49) MAOBPYGL
SCHEMBL5414130 0.83 PTGES2 (0.40) MAOBSMN1; SMN2PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 NFE2L2 1842/4885MAOB 1672/4885CTSL 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.